Marksans Pharma Limited — Updates, 22-11-2024: Press Release

Marksans Pharma Ltd. has received final USFDA approval for its Abbreviated New Drug Application (ANDA) for Loratadine Tablets USP 10 mg. This product will be marketed as a generic alternative to Bayer Healthcare's Claritin, aimed at treating allergic rhinitis and other allergy symptoms such as itching and sneezing. The approval positions Marksans to capitalize on the growing demand for over-the-counter antihistamines, potentially enhancing its market presence. This development underscores the company's ability to expand its portfolio in the competitive generics market, likely contributing positively to future revenue streams. Watch closely for how this approval may affect Marksans' market performance and growth trajectory.